We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+8.97%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
-$24.8M
Cap. Flow
-$295M
Cap. Flow %
-10.7%
Top 10 Hldgs %
47.94%
Holding
172
New
14
Increased
31
Reduced
25
Closed
39

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$27.4M
2
SHPG
Shire pic
SHPG
+$25.4M
3
ILMN icon
Illumina
ILMN
+$22.1M
4
MDVN
MEDIVATION, INC.
MDVN
+$19.9M
5
HCA icon
HCA Healthcare
HCA
+$14.3M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$72.3M
2
ALKS icon
Alkermes
ALKS
+$45.9M
3
AET
Aetna Inc
AET
+$36.3M
4
MDRX
Veradigm Inc. Common Stock
MDRX
+$23M
5
AKRX
Akorn Inc
AKRX
+$22M

Sector Composition

Rank Sector Weight
1 Healthcare 88.47%
2 Real Estate 3.59%
3 Financials 0%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTR icon
26
Ventas
VTR
$44.7B
$20.8M 0.76%
369,266
– –
DOC
27
DELISTED
PHYSICIANS REALTY TRUST
DOC
$20.8M 0.75%
1,230,772
– –
PBYI icon
28
Puma Biotechnology
PBYI
$402M
$20.4M 0.74%
260,200
+165,000
+173% +$13M
IBB icon
29
iShares Biotechnology ETF
IBB
$9.52B
$19.5M 0.71%
173,010
– –
MPT
30
Medical Properties Trust
MPT
$2.81B
$18M 0.65%
1,564,060
– –
NBIX icon
31
Neurocrine Biosciences
NBIX
$18.7B
$17.6M 0.64%
311,460
-64,400
-17% -$3.27M
ENDP
32
DELISTED
Endo International plc
ENDP
$17.5M 0.64%
286,348
-33,973
-11% -$2.06M
NVO
33
Novo Nordisk
NVO
$228B
$17.1M 0.62%
589,200
– –
MCK icon
34
McKesson
MCK
$101B
$16.3M 0.59%
82,862
+15,000
+22% +$2.83M
HZNP
35
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$16.3M 0.59%
749,900
+587,000
+360% +$11.4M
STJ
36
DELISTED
St Jude Medical
STJ
$15.8M 0.57%
255,810
+94,300
+58% +$5.95M
MDCO
37
DELISTED
Medicines Co
MDCO
$15M 0.54%
401,970
-222,330
-36% -$8.4M
IPXL
38
DELISTED
Impax Laboratories, Inc.
IPXL
$14.7M 0.53%
344,683
– –
UTHR icon
39
United Therapeutics
UTHR
$26.2B
$14.6M 0.53%
93,100
-89,500
-49% -$13M
PRTK
40
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$14.5M 0.52%
762,581
– –
OHI icon
41
Omega Healthcare
OHI
$15B
$14.5M 0.52%
413,116
– –
BMY icon
42
Bristol-Myers Squibb
BMY
$132B
$13.9M 0.51%
202,600
-332,640
-62% -$22M
SNY icon
43
Sanofi
SNY
$103B
$13M 0.47%
+305,000
New +$14M
ALNY icon
44
Alnylam Pharmaceuticals
ALNY
$27.4B
$12.9M 0.47%
137,495
-143,979
-51% -$13.3M
BXLT
45
DELISTED
BAXALTA INC COM STK (DE)
BXLT
$12.5M 0.45%
319,600
– –
ANAC
46
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$12.4M 0.45%
110,038
+44,638
+68% +$4.92M
TMO icon
47
Thermo Fisher Scientific
TMO
$214B
$12.3M 0.44%
86,395
– –
BAX icon
48
Baxter International
BAX
$13.8B
$12.2M 0.44%
319,600
– –
CPHD
49
DELISTED
Cepheid Inc
CPHD
$12.2M 0.44%
+333,590
New +$11.9M
WELL.PRI
50
DELISTED
Welltower Inc.
WELL.PRI
– –
-200,000
Closed -$12M
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, Tekla Capital Management held 172 positions worth $2.76B, down 0.89% from $2.78B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Tekla Capital Management withdrew a net $295M in Q4 2015, closing 39 positions and reducing 25 holdings. Its most notable exit was Aetna Inc, an estimated $36.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 81% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Sanofi worth $13M.

  • Tekla Capital Management's largest Q4 2015 buy was Sanofi: 305,000 shares worth $13M.
  • Tekla Capital Management added most to Allergan plc in Q4 2015, an estimated $27.4M increase.
  • Tekla Capital Management's biggest Q4 2015 reduction was Viatris, cutting an estimated $72.3M.
  • Tekla Capital Management fully exited Aetna Inc in Q4 2015, selling an estimated $36.3M.
  • Tekla Capital Management's ten largest holdings make up 48% of its $2.76B portfolio in Q4 2015.
  • Tekla Capital Management opened 14 new positions and closed 39 in Q4 2015.
  • Tekla Capital Management's portfolio value fell 0.89% quarter-over-quarter to $2.76B.

Based on Tekla Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.